# RELATIVITY-098 (NCT05002569)

> A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05002569
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Bristol-Myers Squibb
- Conditions: Melanoma
- Interventions: Nivolumab; Nivolumab + Relatlimab Fixed Dose Combination
- Enrollment: 1093
- Primary outcome: Recurrence Free Survival (RFS)

## Commentary we found

- YouTube: 9
- Podcasts: 9
- X threads: 7

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=relativity-098-nct05002569

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05002569", "email": "<work email>"}; the inbox owner confirms by the emailed link.